valuation model, page-14

Agree with worthind ATC must get more than the two deals stated in the previous post since it has been taken all the way to end of Phase 3 and has shown significant second line advances in treatment compared to the current gold standard of care. the amount of de risking compared to the other 2 deals is tremendous. Alot of the bbig pharma are facing a worrying time with their drugs coming off patent so it should provide for an opportunity for ATC considering it can be in the market within 12 months.